			Patentieno (tabentera cinco), duo del Partimetro de Commento
Inder the Pap	envork Reduction Act of 1995, no persons are required to respond to a collection of information u	ntess it contains a valid OMB control number	
	Substitute for form 1449A/PTO	Com	plete if Known
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	11/709,045
	(use as many sheets as necessary)		
		Filing Date	November 10, 2000
		First Named Inventor	M. Rigdon Lentz
		Group Art Unit	1647
		Examiner Name	Lorraine Spector
Sheet	1 1 of 1 4	Attorney Docket Number	I EN 102

				U.S. PATENT DOC	UMENTS	
Examiner Cite Initials* No.1		US Patent Docume		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevar Passages or Relevant Figures Appear
		Number Kind Co (if kno				
		2002/0114728	Kulisl	ı, et al.	08-22-2002	
		2003/0129130	Guire	, et al.	07-10-2003	
			-			
	 	-				
		-	_			

-			Ì			
			_			
		1	1			

	,				OREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No.1	Cite No.1		Foreign Patent Docum	nent	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
		Office.3	Number*	Kind Code ^d (if known)					
		PCT	WO 03/056896		Molecular Staging, Inc.	07-17-2003		T	
			2 130 069 (w/ Eng. Abstract)		Inst Ehlemento-organicheskikh S	05-10-1999			
				 					
				-				_	
	 			 				-	

Examiner's	Date (Considered
Signature		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assessant Commission for Patent Washington, DC 20231.

¹ Unique polition designation number ² Geo attached Kinds of U.S. Patent Documents. ² Einer Office that issued the document, by the builders one (WIPO Standard STS), ³ Fox Japanese patent documents, be indication of the year of the enign of the Einperior number of the patent of the patent of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant to place a check mark here if English language Translation is estimated.

				Falsiti dan Habilitats Once, C.S. DEPARTIEDS OF COMMO				
Inder the Pap	erwork Reduction Act of	1995, no person	s are required to respond to a collection of information u	niess it contains a valid OMB control number				
	Substitute for	form 1449	APTO	Complete if Known				
	STA	TEME	TION DISCLOSURE NT BY APPLICANT any sheets as necessary)	Application Number	11/709,045			
		(,,	Filing Date	November 10, 2000			
				First Named Inventor	M. Rigdon Lentz			
				Group Art Unit	1647			
				Examiner Name	Lorraine Spector			
Sheet	2	of	4	Attorney Docket Number	LEN 102			

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), (lide of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, et.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
		ADOLF and FRÜHBEIS, "Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity.", Cytokine, 4(3):180-184 (1992).	
		BJORNBERG, et al., "Mechanisms involved in the processing of the p55 and the p75 tumor necrosis factor (TNF) receptors to soluble receptor forms", Lymphokine Cytokine Res., 13(3):203-11 (1994).	
		CSEHI, et al., "Tumor necrosis factor (TNF) interferes with insulin signaling through the p55 TNF receptor death domain", Biochem Biophys Res Commun, 329(1):397-405 (2005).	
		FENG, "Regulatory roles and molecular signaling of TNF family members in osteoclasts", Gene, 350(1):1-13 (2005).	
		GADDUCCI, et al., "Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer", Gynecol Oncol, 58(2):184-8 (1995).	
		GRELL, et al., "The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor", Proc Natl Acad Sci U S A., 95(2):570-5 (1998).	
		GROSEN, et al., "Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy", Gynecol Oncol, 50(1):68-77 (1993).	
		HASEGAWA, et al., "increased soluble turnor necrosis factor receptor levels in the serum of elderly people", Gerontology, 46(4):185-8 (2000).	
		HOLTMANN, et al., "The emerging distinct role of TNF-receptor 2 (p80) signaling in chronic inflammatory disorders", Arch Immunol Ther Exp (Warsz), 50(4):279-88 (2002).	
		JABLONSKA, et al., "Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients", Eur Cytokine Netw, 9(2):155-9 (1998).	
		LIU, et al., "Molecular mechanism of TNF signaling and beyond", Cell Res, 15(1):24-7 (2005).	Г

Examiner's	Date Considered	
Signature		
olgilatule		

Burdan Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, Oc 20231. DO NOT SEND FEES OR COMPLETED FORMSTO THIS ADDRESS. SENT TO. Assistant Commission for Patent, Washington, Oc 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

^{**}Linking clatifor designation number * See attached Kinds of U.S. Patent Documents.** Each of life to that issued the document, by the Acutetic rode (MIPO Standard STS). * For Japanese patent document, be indication of he year of the reingly on the Emperor must proced the seisal may have the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant to place a check mark here if English language Translation is estudy.

Substitute for form 1449A/PTO

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Co	omplete if Known
Application Number	11/709,045
Filing Date	November 10, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	1647
Examiner Name	Lorraine Spector

LEN 102

No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, dily and/or country where published	72
	MACALLAN, et al., "Development of a novel TNF alpha ligand-receptor binding assay for screening NATCHEM Libraries", J Recept Signal Transduct Res, 17(1-3):521-9 (1997).	
	MAIER, et al., "Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study", J Neurotrauma, 22(7):822-35 (2005).	
	MUC-WIERZGON, et al., "Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer", J Exp Clin Cancer Res, 22(2):171-8 (2003).	
	NOPHAR, et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor", [EMBO J, 9(10):3289-78 (1990).	
	ONSRUD, et al., "Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer", Gynecol Oncol, 57(2):183-7 (1995).	
	ONSRUD, et al., "Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer", Tumour Biol, 17(2):90-6 (1996).	
	RZYMSKI, et al., "Serum tumor necrosis factor alpha receptors p55/p75 ratio and ovarian cancer detection", <i>J Gynaecol</i> Obstef, 88(3):292-8 (2005).	
	SERWiN, et al., "[Soluble tumor-necrosis-factor-alpha receptor type-1 as a marker of activity of psoriasis vulgaris and effects of its treatment]", Przeg/ Lek, 62(2):95-7 (2005).	
	SERWiN, et al., "Soluble tumor necrosis factor alpha receptor type 1 in psoriasis patients treated with narrowband ultraviolet B" Photodermatol Photoimmunol Photomed, 21(4):210-1 (2005).	
	SHAI, et al., "A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women wifth type 2 diabetes", Diabetes Care, 28(6):1376-82 (2005).	
	SUKHIKH, et al., "Disorders in cytokine gene expression in endometrial hyperplasia and effect of hormone therapy", Bull Exp Biol Med., 139(2):235-7 (2005).	
		No." Iden (book, magazine, journal, serial, symposium, cataliae, etc.), dase, page(s), volumie-steue number(s), MACALLAN, et al., "Development of patients-rely and/or control water published Libraries", J. Rocept Signal Transduct Res. 17(1-3):521-9 (1991). MAIER, et al., "Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study", J. Neurofraume, 22(7):522-36 (2005). MUC-WIERZGON, et al., "Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer", J. Exp. Clin Cancer Res, 22(2):171-8 (2003). NOPHAR, et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid equence data of its soluble form, encodes both the cell surface and a soluble form of the receptor", EMBO. J. 9(10):2369-78 (1995). ONSRUD, et al., "Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for perithelial ovarian cancer", Gynecol Oncol., 57(2):183-7 (1995). ONSRUD, et al., "Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer", Gynecol Oncol., 57(2):183-7 (1995). ONSRUD, et al., "Soluble tumor necrosis factor alpha receptor sp55/p75 ratio and ovarian cancer detection", J Gynaecol Ostete, 88(3):282-8 (2005). SERWINI, et al., "Soluble tumor-necrosis-factor-alpha receptor type-1 as a marker of activity of psoriasis vulgaris and effects of its treatment", Przegl Lek, 62(2):95-7 (2005). SERWINI, et al., "Soluble tumor-necrosis-factor-alpha receptor type-1 in psoriasis patients treated with narrowband ultraviolet B" Photodermatol Photoimmunol Photomed, 21(4):210-1 (2005). SERWINI, et al., "Spoutelle tumor necrosis factor alpha receptor type-1 in psoriasis patients treated with narrowband ultraviolet B" Photodermatol Photoimmunol Photomed, 21(4):210-1 (2005). SERWINI, et al., "Spoutelle tumor necrosis factor alpha receptor in

OTHER ART - NON PATENT LITERATURE DOCUMENTS.

Attorney Docket Number

Examiner's Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ⁴ For Japansee patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ When springer test profits by a indicated on the document turble (WiPO Standard ST. 16) sessable. ⁴ Applicant to place a check mark here if English language. Translation is attached.

					- symbol mathematical or or occurrence of comments		
Under the Pa;	serwark Reduction Act	of 1995, no persor	ns are required to respond to a collection of information u	ntess it contains a valid CMB control number			
Substitute for form 1449A/PTO				Complete if Known			
		ATEME	TION DISCLOSURE :NT BY APPLICANT any sheets as necessary)	Application Number	11/709,045		
			-	Filing Date	November 10, 2000		
				First Named Inventor	M. Rigdon Lentz		
				Group Art Unit	1647		
				Examiner Name	Lorraine Spector		
Sheet	4	of	4	Attorney Docket Number	I EN 102		

xaminer's I	Cite	OTHER ART NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	T =
Initials*	No.1	item (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
		TESAROVA, et al., "Soluble TNF and IL-2 receptors in patients with breast cancer", Med Sci Monit, 6(4):661-7 (2000).	
		THEISS, et al., "Tumor Necrosis Factor (TNF) {alpha} Increases Collagen Accumulation and Proliferation in Intestinal Myofibroblasts via TNF Receptor 2", J Biol Chem, 280(43):36099-109 (2005).	
		WAJANT, et al., "Turnor necrosis factor signaling", Cell Death Differ, 10(1):45-65 (2003).	T
		WOZEL, "[Etanercept An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis.]" Haufarzt, 56(9):819-830 (2005).	T
			Γ
			ľ
			ľ
			T

Examiner's	Date Considered	
Signature		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEXOP TESS OR COMPLETED FORMS OF TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{**} Unique diation designation number** See attached Kinds of U.S. Patent Documents.** Einst office that issued the document, by the volveter onder (MIPO Standard ST3).** For Janapere spetant documents, the indication of the year of the single of the Emperor must proceed the serial container of the patent document type of the single procedure of the patent document type of the single procedure of the patent document type of the single procedure of the patent document type of the single procedure of the patent document type of the patent document of the patent document type of the patent ty